Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT02942355
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Hamdy A. Azim
- Target Recruit Count
- 160
- Registration Number
- NCT02917005
- Locations
- 🇿🇦
Wits Oncology center, Johannesburg, South Africa
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Shannon Puhalla
- Target Recruit Count
- 7
- Registration Number
- NCT02913430
- Locations
- 🇺🇸
Magee-Womens Hospital UPMC, Pittsburgh, Pennsylvania, United States
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT02907918
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 19
- Registration Number
- NCT02905318
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦London Regional Cancer Program, London, Ontario, Canada
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Emory University
- Target Recruit Count
- 71
- Registration Number
- NCT02897375
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Palbociclib and Pembrolizumab in Central Nervous System Metastases
- Conditions
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT02896335
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 388
- Registration Number
- NCT02894398
- Locations
- 🇩🇪
Research Site, Wilhelmshaven, Germany
Palbociclib With Everolimus + Exemestane In BC
- Conditions
- Interventions
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT02871791
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.